Mynd Tests MAP, Blood Biomarker for MS Diagnosis

Mynd Tests MAP, Blood Biomarker for MS Diagnosis

312872

Mynd Tests MAP, Blood Biomarker for MS Diagnosis

Mynd Diagnostics is launching a clinical study to test the ability of a blood biomarker, which the company coined Mynd anti-inflammatory peptide (MAP), to help in the diagnosis and monitoring of multiple sclerosis (MS). Starting in the first quarter of 2022, the company will collect blood samples from diagnosed patients to compare their biomarker levels against control samples. Pending positive results, the company plans to apply to the U.S. Food and Drug Administration (FDA) as early…

You must be logged in to read/download the full post.